Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Citi
McKinsey
Baxter
Cerilliant
US Army
Merck
Accenture
Covington

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,603,514

« Back to Dashboard

Summary for Patent: 8,603,514
Title:Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.
Inventor(s): Yang; Robert K. (Fushing, NY), Fuisz; Richard C. (McLean, VA), Myers; Garry L. (Kingsport, TN), Fuisz; Joseph M. (Washington, DC)
Assignee: MonoSol RX, LLC (Warren, NJ)
Application Number:11/775,484
Patent Claim Types:
see list of patent claims
Composition; Delivery; Use;

Drugs Protected by US Patent 8,603,514

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-001 Aug 30, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-003 Aug 10, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-002 Aug 30, 2010 RX Yes No ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION ➤ Subscribe
Indivior Inc SUBOXONE buprenorphine hydrochloride; naloxone hydrochloride FILM;BUCCAL, SUBLINGUAL 022410-004 Aug 10, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,603,514

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,685,437 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom ➤ Subscribe
8,906,277 Process for manufacturing a resulting pharmaceutical film ➤ Subscribe
8,652,378 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions ➤ Subscribe
2,016,206,639 ➤ Subscribe
8,900,498 Process for manufacturing a resulting multi-layer pharmaceutical film ➤ Subscribe
7,910,031 Process for forming an ingestible thin film with non-self-aggregating uniform heterogeneity ➤ Subscribe
9,108,340 Process for manufacturing a resulting multi-layer pharmaceutical film ➤ Subscribe
7,824,588 Method of making self-supporting therapeutic active-containing film ➤ Subscribe
8,017,150 Polyethylene oxide-based films and drug delivery systems made therefrom ➤ Subscribe
8,765,167 Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,603,514

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 536868 ➤ Subscribe
Austria 536869 ➤ Subscribe
Austria 553746 ➤ Subscribe
Australia 2002332118 ➤ Subscribe
Australia 2002348432 ➤ Subscribe
Australia 2002362772 ➤ Subscribe
Australia 2004319243 ➤ Subscribe
Australia 2005292271 ➤ Subscribe
Australia 2006287342 ➤ Subscribe
Australia 2006322050 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Moodys
Boehringer Ingelheim
McKesson
Covington
Daiichi Sankyo
Fish and Richardson
Cerilliant
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot